ReviewMini reviews in medicinal chemistry2026
A Comprehensive Update on the Anti-cancer and Anti-microbial Potential of Marine Organisms Derived Natural Products.
Review in Mini reviews in medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Marine organisms produce a diverse array of secondary metabolites with significant pharmacological potential, particularly in the development of anti-cancer, anti-microbial, antifungal, and anti-viral therapies. Despite challenges in isolation and cultivation, marine-derived compounds, such as Didemnin B, Psammaplin A, and Dolastatin, have shown promise in cancer treatment, while other metabolites exhibit potent activity against drug-resistant bacteria, fungi, and viruses. These compounds have excellent potential for treating various infections, for example, MRSA (eicosapentaenoic acid and fridamycin), Candida albicans (aurantoside K), and HIV-1 and HIV-2 (sulfoquinovosyl diacylglycerol). These unique compounds offer new avenues in drug discovery, addressing current limitations in traditional therapies. This review provides an overview of the pharmacological potential of marine organisms, focusing on their applications in overcoming drug resistance and developing novel treatments for cancer, infections, and viral diseases. Sustainable approaches for harvesting these compounds are essential for future research.
Indexed as
Identifiers
41603174What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.